Cargando…

Erratum to: The impact of benzodiazepine use in patients enrolled in opioid agonist therapy in Northern and rural Ontario

Detalles Bibliográficos
Autores principales:	Franklyn, Alexandra M., Eibl, Joseph K., Gauthier, Graham, Pellegrini, David, Lightfoot, Nancy E., Marsh, David C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369184/ https://www.ncbi.nlm.nih.gov/pubmed/28351357 http://dx.doi.org/10.1186/s12954-017-0140-7

Ejemplares similares

The impact of benzodiazepine use in patients enrolled in opioid agonist therapy in Northern and rural Ontario
por: Franklyn, Alexandra M., et al.
Publicado: (2017)

The impact of cannabis use on patients enrolled in opioid agonist therapy in Ontario, Canada
por: Franklyn, Alexandra M., et al.
Publicado: (2017)

Concurrent psychiatry for patients enrolled in opioid agonist treatment: a propensity score matched cohort study in Ontario Canada
por: Morin, Kristen A., et al.
Publicado: (2019)

Correction to: Concurrent psychiatry for patients enrolled in opioid agonist treatment: a propensity score matched cohort study in Ontario Canada
por: Morin, Kristen A., et al.
Publicado: (2019)

A retrospective cohort study evaluating correlates of deep tissue infections among patients enrolled in opioid agonist treatment using administrative data in Ontario, Canada
por: Morin, Kristen A., et al.
Publicado: (2020)

A cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (OAT) across Ontario, Canada, using administrative health data
por: Morin, Kristen A., et al.
Publicado: (2020)

Evaluating the effectiveness of concurrent opioid agonist treatment and physician-based mental health services for patients with mental disorders in Ontario, Canada
por: Morin, Kristen A., et al.
Publicado: (2020)

The opioid crisis: past, present and future policy climate in Ontario, Canada
por: Morin, Kristen A., et al.
Publicado: (2017)

Evidence of increased Fentanyl use during the COVID-19 pandemic among opioid agonist treatment patients in Ontario, Canada
por: Morin, Kristen A., et al.
Publicado: (2021)

Characterizing the Use of Telepsychiatry for Patients with Opioid Use Disorder and Cooccurring Mental Health Disorders in Ontario, Canada
por: LaBelle, Brittanie, et al.
Publicado: (2018)

Evaluating the Impact of Prescribed Versus Nonprescribed Benzodiazepine Use in Methadone Maintenance Therapy: Results From a Population-based Retrospective Cohort Study
por: Eibl, Joseph K., et al.
Publicado: (2019)

Erratum to: Access to primary care in adults in a provincial correctional facility in Ontario
por: Green, Samantha, et al.
Publicado: (2016)

Erratum to: Agonist Opioid Treatment as historical comprehensive treatment (‘Dole & Nyswander’ methodology) is associated with better toxicology outcome than Harm Reduction Treatment
por: Bizzarri, Jacopo V., et al.
Publicado: (2017)

Negative Impact of Amphetamine-Type Stimulant Use on Opioid Agonist Treatment Retention in Ontario, Canada
por: Morin, Kristen A., et al.
Publicado: (2021)

Evaluating the Effectiveness of First-Time Methadone Maintenance Therapy Across Northern, Rural, and Urban Regions of Ontario, Canada
por: Eibl, Joseph K., et al.
Publicado: (2015)

Erratum to: Pain Management in Patients with Cancer: Focus on Opioid Analgesics
por: Leppert, Wojciech
Publicado: (2011)

Opioid Prescribing and Consumption Trends in Outpatient Plastic Surgery: Erratum
por: Rose, Katherine R., et al.
Publicado: (2018)

Erratum. Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet’s Pathway to Prevention. Diabetes Care 2019;42:2228–2236
por: Sims, Emily K., et al.
Publicado: (2020)

Geographic distribution of Ontario pharmacists: A focus on rural and northern communities
por: Timony, Patrick, et al.
Publicado: (2022)

The effect of opioid analgesics, benzodiazepines, gabapentinoids, and opioid agonist treatment on mortality risk among opioid-dependent people.
por: Bharat, Chrianna, et al.
Publicado: (2022)

Erratum: Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats
por: Ezrokhi, Michael, et al.
Publicado: (2015)

Erratum: Incorrect Title of the Author. Opioid Pharmacotherapy for Chronic Noncancer Pain: The American Experience
por: Chapman, C. Richard
Publicado: (2013)

Erratum to: Identity-by-descent-based heritability analysis in the Northern Finland Birth Cohort
por: Browning, Sharon R., et al.
Publicado: (2013)

Measuring treatment attrition at various stages of engagement in Opioid Agonist Treatment in Ontario Canada using a cascade of care framework
por: Tahsin, Farah, et al.
Publicado: (2022)

Association of prescribed oral stimulants on cocaine use among patients enrolled in opioid agonist treatment: A retrospective longitudinal cohort study
por: Tatangelo, Mark, et al.
Publicado: (2022)

Evidence of Increased Age and Sex Standardized Death Rates Among Individuals Who Accessed Opioid Agonist Treatment Before the Era of Synthetic Opioids in Ontario, Canada
por: Morin, Kristen A, et al.
Publicado: (2021)

Influence of genetic variants of opioid-related genes on opioid-induced adverse effects in patients with lung cancer: A STROBE-compliant observational study: Erratum
Publicado: (2021)

The growing problem of co-treatment with opioids and benzodiazepines
por: Karaca-Mandic, Pinar, et al.
Publicado: (2017)

Erratum to “Preconditioning of Rat Bone Marrow-Derived Mesenchymal Stromal Cells with Toll-Like Receptor Agonists”
por: Evaristo-Mendonça, Fabiana, et al.
Publicado: (2020)

Evaluating the association between urine drug screening frequency and retention in opioid agonist treatment in Ontario, Canada: a retrospective cohort study
por: Morin, Kristen A, et al.
Publicado: (2022)

A Response Surface Model Exploration of Dosing Strategies in Gastrointestinal Endoscopies Using Midazolam and Opioids: Erratum
Publicado: (2016)

A study protocol for a quasi-experimental community trial evaluating the integration of indigenous healing practices and a harm reduction approach with principles of seeking safety in an indigenous residential treatment program in Northern Ontario
por: Marsh, T. N., et al.
Publicado: (2021)

Erratum to: Comparative hydrolysis of P2 receptor agonists by NTPDases 1, 2, 3 and 8. Purinergic Signalling
por: Kukulski, F., et al.
Publicado: (2005)

ERRATUM: Figure Legend Correction. Characteristics in Molecular Vibrational Frequency Patterns between Agonists and Antagonists of Histamine Receptors
por: Oh, S. June
Publicado: (2013)

Erratum in: SZN-413, a FZD4 Agonist, as a Potential Novel Therapeutic for the Treatment of Diabetic Retinopathy
Publicado: (2022)

Erratum to: Comparative Analysis of Length of Stay and Inpatient Costs for Orthopedic Surgery Patients Treated with IV Acetaminophen and IV Opioids vs. IV Opioids Alone for Post-Operative Pain
por: Hansen, Ryan N., et al.
Publicado: (2016)

Erratum: Differences in phosphatemia and frequency of consumption of dietary sources of phosphorus in hemodialysis patients in southern and northern Brazil
Publicado: (2018)

Community trial evaluating the integration of Indigenous healing practices and a harm reduction approach with principles of seeking safety in an Indigenous residential treatment program in northern Ontario
por: Morin, K. A., et al.
Publicado: (2022)

Erratum to: The effects of the adenosine A3 receptor agonist IB-MECA on sodium taurocholate-induced experimental acute pancreatitis
por: Prozorow-Krol, Beata, et al.
Publicado: (2013)

Erratum to: Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ufsik8u0igv2dl316jc3sfkkov